A wave of lawsuits is moving through the courts against the two companies that make most of the GLP-1 drugs on the market. Novo Nordisk faces the bulk of the claims, and Eli Lilly faces at least one of its own. If you take Ozempic, Wegovy, or a similar drug, or hope to someday, these cases could change what you pay and what your doctor tells you about your options. None of them has been decided yet, but the arguments inside them are worth understanding.
Washington state has filed its own suit against Novo Nordisk, and this one carries extra weight because a state government, not an individual patient, is bringing the claim. The state argues that Novo Nordisk's marketing and pricing of Ozempic and Wegovy harmed consumers, and it is asking the court for remedies that could include refunds or changes to how the drugs are priced going forward. Because the case is active, there is no outcome yet, but a ruling in the state's favor could set a pattern that other states or private plaintiffs point to in their own cases. If you have paid out of pocket for either drug, this is the case most likely to affect your wallet directly.
One of the private lawsuits, Milby v. Novo Nordisk, takes a narrower and more direct approach. It alleges that the company used unfair pricing and distribution practices that inflated what patients and insurers actually pay for Ozempic and Wegovy. This differs from claims about competition or patents; it focuses on the price tag itself and argues that the amount charged does not reflect fair market practices. The case is still pending, so no court has yet decided whether the pricing practices described were in fact unlawful. Anyone who has struggled with the cost of these drugs at the pharmacy counter may want to watch how this claim develops.
A separate suit, Doyle v. Novo Nordisk, raises a different kind of concern. It claims the company misled patients and consumers not just about pricing but about how effective its GLP-1 drugs actually are. Combining a pricing claim with an effectiveness claim raises the stakes, because it suggests patients may have paid a premium based on representations the suit says were not accurate. No ruling has been issued, and the claims remain allegations rather than established facts. Still, this case is worth tracking because it touches on the information patients rely on when deciding whether a drug is worth its cost.
Several of the pending suits, including Crye v. Novo Nordisk and the antitrust claims tied to Prestage and DiChiaro, argue that the company used pricing and patent strategies to keep cheaper GLP-1 competitors off the market. The theory behind these cases is that limiting competition, rather than simply setting a high price, is what has kept costs elevated for patients. If courts find merit in these claims, the effect could reach further than a single settlement, because removing barriers to competition could open the door to lower cost alternatives across the board. For now, these remain allegations working their way through the legal system, and no timeline for resolution has been set.
Not every case in this group involves Novo Nordisk. Eisbrouch v. Eli Lilly targets how that company markets and labels its own GLP-1 drugs, and the suit argues that its practices could reshape the guidance doctors receive when prescribing these medications. This matters because prescriber guidance shapes which drug a doctor recommends and how it is described to a patient weighing the options. The case is still pending, and the full scope of what a ruling might change is not yet clear. Patients who take a Lilly GLP-1 drug, or whose doctor is weighing one against a Novo Nordisk product, may see the effects of this case reflected in future labeling or prescribing guidance.
None of these cases has reached a final ruling, and it may be some time before any of them do. In the meantime, it is reasonable to keep two things in mind. First, a pending lawsuit is not proof of wrongdoing, and the claims described here are allegations that a court has not yet evaluated. Second, these cases are worth watching precisely because so many of them, across different plaintiffs and different legal theories, point at the same basic question: whether pricing and competition practices for GLP-1 drugs have kept costs higher than they should be. If you rely on one of these medications, following how these cases resolve may tell you more about your future costs than anything the companies themselves are currently saying.
Key details
A Washington state lawsuit against Novo Nordisk could bring refunds or price cuts.
One lawsuit claims Novo Nordisk's pricing inflated what you pay for Ozempic and Wegovy.
Another suit alleges Novo Nordisk misled patients about GLP-1 effectiveness and pricing.
Several suits argue Novo Nordisk used illegal tactics to limit GLP-1 competition.
A separate Eli Lilly case could reshape prescriber guidance for GLP-1 drugs.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.